Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca Installs Several Cellectricon Ion Channel Screening Platforms

NEW YORK, June 28 (GenomeWeb News) - AstraZeneca has installed several of Cellectricon's DynaFlow ion channels screening platforms worldwide, Cellectricon said today.

 

Cell-Based Assay News, a GenomeWeb News sister publication, reported in June 2004 that AstraZeneca had decided to use DynaFlow in its ion channel drug-discovery program. Cellectricon said today that AstraZeneca has placed multiple orders for DynaFlow systems since that time.

 

Financial terms of the deal were not disclosed.

 

DynaFlow is based on a computer-controlled microfluidic chip, and is designed to be used with any cell, patch-clamp configuration, active substance, and ion channel, Cellectricon said.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.